Skip to search formSkip to main contentSkip to account menu

Overall Survival

A measure of the time until death from any cause.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression‐free survival, as… 
Highly Cited
2017
Highly Cited
2017
BACKGROUND Nivolumab combined with ipilimumab resulted in longer progression‐free survival and a higher objective response rate… 
Highly Cited
2015
Highly Cited
2015
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously… 
Review
2011
Review
2011
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more… 
Highly Cited
2010
Highly Cited
2010
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3… 
Highly Cited
2009
Highly Cited
2009
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free… 
Highly Cited
2008
Highly Cited
2008
PURPOSE As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role…